New trials conducted through Moderna Inc. revealed that their COVID-19 vaccine gave the impression and worked well with the elderly. The effects of the trials were published in the New England Journal of Medicine and revealed that the vaccine produced antibodies that neutralized the virus to degrees. similar to those noticed in adults. Moderna is already testing a dose of one hundred micrograms of its Phase 3 vaccine, and the positive effects would make it the first vaccine in the US. But it’s not the first time
The most recent studies were conducted as a continuation of the company’s Phase I protection trials, which were conducted first in others over the age of 18 to 55. At this end, the researchers tested two doses of the Moderna vaccine: 25 micrograms and one hundred micrograms. – in 40 adults over 56 to 70 and 71 and more.
In the process, they found that in adults who won two 100 microgram dose injections 28 days apart, the vaccine produced immune responses more or less similar to those produced in young adults. Although older adults experienced side effects such as headache, fatigue, aches, chills, injection site, they were mild to meditate on the intensity scale. Explaining the side effects of the study, which provided a complete picture of the safety of the vaccine, the researchers said the side effects were more or less comparable to those of high-dose influenza vaccines.
Read: COVID-19 Vaccine Test Plans Revealed Through Moderna, Pfizer Amid Calls For Transparency
Read: Modern COVID-19 Vaccine: another 13,194 people sign up for Phase 3 trials
Recently, Moderna has become the first company to publish comprehensive clinical trial plans amid Pfizer. Moderna’s calls for transparency is one of nine companies whose COVID-19 candidate vaccine is in the latter stages of clinical trials, while the new coronavirus outbreak has another US-based pharmaceutical company. Pfizer, who is also conducting Phase 3 trials in the United States, allegedly complied at a time with a similar decision, leading to increased pressure on the remaining corporations to do the same.
Read: Trump Management Symptoms $1. 5 Billion Deal with Modern per dose of COVID-19 vaccine
Read: COVID-19: Modern and Pfizer to include volunteers with HIV in the final phase of vaccine trials